Synthesis of β-maltooligosaccharides of glycitein and daidzein and their anti-oxidant and anti-allergic activities

Article abstract of DOI:10.3390/molecules15085153

The production of β-maltooligosaccharides of glycitein and daidzein using Lactobacillus delbrueckii and cyclodextrin glucanotransferase (CGTase) as biocatalysts was investigated. The cells of L. delbrueckii glucosylated glycitein and daidzein to give their corresponding 4′- and 7-O-β-glucosides. The β-glucosides of glycitein and daidzein were converted into the corresponding β-maltooligosides by CGTase. The 7-O-β- glucosides of glycitein and daidzein and 7-O-β-maltoside of glycitein showed inhibitory effects on IgE antibody production. On the other hand, β-glucosides of glycitein and daidzein exerted 2,2-diphenyl-1- picrylhydrazyl (DPPH) free-radical scavenging activity and supeoxide-radical scavenging activity.

Full text of DOI:10.3390/molecules15085153

Molecules 2010, 15, 5153-5161; doi:10.3390/molecules15085153
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis of β-Maltooligosaccharides of Glycitein and Daidzein
and their Anti-Oxidant and Anti-Allergic Activities
Kei Shimoda 1,* and Hiroki Hamada 2,*
1
Department of Chemistry, Faculty of Medicine, Oita University, 1-1 Hasama-machi, Oita 879-5593,
Japan
2
Department of Life Science, Okayama University of Science, 1-1 Ridai-cho, Kita-ku, Okayama
700-0005, Japan
* Authors to whom correspondence should be addressed; E-Mails: shimoda@med.oita-u.ac.jp (K.S.);
hamada@dls.ous.ac.jp (H.H.); Tel. +81-97-586-5606 (K.S.); +81-86-256-9473 (H.H.);
Fax: +81-97-586-5619 (K.S.); +81-86-256-8468 (H.H.).
Received: 10 June 2010; in revised form: 25 July 2010 / Accepted: 27 July 2010 /
Published: 29 July 2010
Abstract: The production of β-maltooligosaccharides of glycitein and daidzein using
Lactobacillus delbrueckii and cyclodextrin glucanotransferase (CGTase) as biocatalysts
was investigated. The cells of L. delbrueckii glucosylated glycitein and daidzein to give
their corresponding 4'- and 7-O-β-glucosides. The β-glucosides of glycitein and daidzein
were converted into the corresponding β-maltooligosides by CGTase. The 7-O-β-
glucosides of glycitein and daidzein and 7-O-β-maltoside of glycitein showed inhibitory
effects on IgE antibody production. On the other hand, β-glucosides of glycitein and
daidzein exerted 2,2-diphenyl-1-picrylhydrazyl (DPPH) free-radical scavenging activity
and supeoxide-radical scavenging activity.
Keywords: glycitein; daidzein; β-maltooligosaccharides; anti-allergic activity; anti-
oxidant activity
1. Introduction
Glycitein and daidzein are important and bioactive isoflavones isolated from soybeans whose
pharmacological properties such as anticancer, anti-inflammatory, neuroprotective, anticarcinogenic

Molecules 2010, 15
5154
effects, and protective effects against bone loss, hormone-dependent and -independent cancers,
cardiovascular diseases, and autoimmune diseases and have been widely studied [1-11]. Despite these
pharmacological activities, their use as medicines and functional food-ingredients is limited, because
they are scarcely soluble in aqueous solution and poorly absorbed through oral administration.
Glycosylation is an important method for the conversion of water-insoluble and unstable organic
compounds into the corresponding water-soluble and chemically stable derivatives. Mizukami et al.
reported that glucosyl conjugation was far more effective than cyclodextrin complexation at enhancing
the water solubility of hydrophobic compounds such as curcumin [12]. Recently, absorption efficiency
of a lipophilic flavonoid, i.e., quercetin, has been reported to be much improved, when converted into
its glycoconjugates [13,14]. Glycosylations of glycitein and daidzein are of importance from the
viewpoint of pharmacological development of soy isoflavones. We report here the synthesis of β-
maltooligosaccharides of glycitein and daidzein by sequential glycosylation with Lactobacillus
delbrueckii and cyclodextrin glucanotransferase (CGTase). We also report their inhibitory activity for
IgE antibody formation, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity, and
supeoxide-radical scavenging activity.
2. Results and Discussion
2.1. Synthesis of β-maltooligosaccharides of glycitein and daidzein
The biotransformation of glycitein (1) was investigated using the cultured cells of L. delbrueckii.
When cells of L. delbrueckii were incubated with glycitein (1) in the presence of glucose for 5 days,
two products, 2 and 3, were isolated from the n-butanol extracts of cell cultures by preparative HPLC
(2, 5% yield; 3, 7%). The chemical structures of 2 and 3 were determined by spectroscopic methods
such as HRFABMS, 1H- and 13C-NMR as glycitein 4'-O-β-D-glucoside (2) [15] and glycitein 7-O-β-D-
glucoside (3) [15]. Next, the glucoside product 2 was further glycosylated by cyclodextrin
glucanotransferase (CGTase) to give two new compounds 4 and 5 in 45 and 39% yield, respectively.
The structures of products 4 and 5 were identified as glycitein 4'-O-β-maltoside and glycitein 4'-O-β-
maltotrioside, which have not been reported before, by HRFABMS, 1H- and 13C-NMR, H-H COSY, C-
H COSY, and HMBC spectra. Also, the glucoside 3 was converted by CGTase to give glycitein 7-O-β-
maltoside (6) and glycitein 7-O-β-maltotrioside (7), which were two new compounds, in 41 and 33%
yield, as shown in Figure 1.
The HRFABMS spectra of 4 and 6 included pseudomolecular ion [M+Na]+ peaks at 631.1640 for 4
and 631.1641 for 6 (calculated for C28H32O15Na, 631.1639), indicating that each product consisted of
one substrate and two hexoses. The sugar components in these products were determined to be glucose
1
on the basis of their chemical shifts of the carbon signals. The H-NMR spectra showed two proton
signals at δ 5.05 (1H, d, J = 3.2 Hz) and 5.11 (1H, d, J = 7.6 Hz) for 4, and δ 5.07 (1H, d, J = 3.2 Hz)
and 5.19 (1H, d, J = 7.6 Hz) for 6, indicating that the glucoside linkage in these compounds had each
of α- and β-orientations. The HMBC spectra of 4 and 6 included correlations between the proton
signal at δ 5.05 (H-1''') and the carbon signal at δ 80.5 (C-4'') and between the proton signal at δ 5.11
(H-1'') and the carbon signal at δ 157.3 (C-4') for 4, and between the proton signal at δ 5.07 (H-1''') and
the carbon signal at δ 79.9 (C-4'') and between the proton signal at δ 5.19 (H-1'') and the carbon signal

Molecules 2010, 15
5155
at δ 152.5 (C-7) for 6. These data indicated that 4 and 6 were β-maltosyl analogues of 1, the sugar
moiety of which was attached at their 4'- (4) and 7-positions (6). Thus, products 4 and 6 were
identified as glycitein 4'-O-β-maltoside (4) and glycitein 7-O-β-maltoside (6), respectively.
The HRFABMS spectrum of 5 and 7 with pseudomolecular ion [M+Na]+ peak [m/z 793.2170 (5)
and 793.2177 (7)] established a molecular formula of C34H42O20 (calcd. 793.2167 for C34H42O20Na),
indicating that each product consisted of one substrate and three hexoses. The sugar components in
these products were identified as glucose on the basis of the chemical shifts of the carbon signals. The
1H-NMR spectra showed three proton signals at δ 5.05 (1H, d, J = 3.2 Hz), 5.07 (1H, d, J = 3.0 Hz),
and 5.12 (1H, d, J = 7.6 Hz) for 5, and δ 5.07 (1H, d, J = 3.2 Hz), 5.09 (1H, d, J = 3.2 Hz), and 5.19
(1H, d, J = 7.6 Hz) for 7, indicating that the glucoside linkage in these compounds had two α-
orientations and one β-orientation. Correlations were observed in the HMBC spectra of 5 and 7
between the proton signal at δ 5.05 (H-1'''') and the carbon signal at δ 78.9 (C-4'''), between the proton
signal at δ 5.07 (H-1''') and the carbon signal at δ 78.8 (C-4''), and between the proton signal at δ 5.12
(H-1'') and the carbon signal at δ 157.6 (C-4') for 5, and between the proton signal at δ 5.07 (H-1'''')
and the carbon signal at δ 79.9 (C-4'''), between the proton signal at δ 5.09 (H-1''') and the carbon
signal at δ 79.7 (C-4''), and between the proton signal at δ 5.19 (H-1'') and the carbon signal at δ 152.5
(C-7) for 7. These data indicated that 5 and 7 were β-maltotriosyl analogues of 1, the sugar moiety of
which was attached at their 4'- (5) and 7-positions (7). Thus, the structures of products 5 and 7 were
determined to be glycitein 4'-O-β-maltotrioside (5) and glycitein 7-O-β-maltotrioside (6), respectively.
Figure 1. Synthesis of β-maltooligosaccharides of glycitein (1) and daidzein (8) by
glycosylation with L. delbrueckii and CGTase.
HO
O
HO
R
O
OH
HO
OH
CGTase
O
R
OH
OH
OH
O
O
HO
HO
O
O
O
OH
OH
n
O
O
1
OH
8
5
7
9
HO
R
O
2
3
R=OCH3: 2
R=H: 9
R=OCH3, n=1: 4
R=OCH3, n=2: 5
R=H, n=1: 11
2'
5'
6
L. delbrueckii
4
3'
4'
10
1'
6'
R=H, n=2: 12
O
OH
OH
R=OCH3: 1
R=H: 8
O
HO
HO
O
R
O
O
CGTase
OH
O
HO
HO
HO
OH
HO
O
O
O
O
HO
OH
HO
R
n
R=OCH3: 3
R=H: 10
O
OH
R=OCH3, n=1: 6
R=OCH3, n=2: 7
R=H, n=1: 13
R=H, n=2: 14
On the other hand, incubation of daidzein (8) with L. delbrueckii cells in the presence of glucose for
5 days gave daidzein 4'-O-β-D-glucoside (9, 5%) [16] and daidzein 7-O-β-D-glucoside (10, 5%) [16].
The glucoside 9 was converted by CGTase to give daidzein 4'-O-β-maltoside (11) [16] and daidzein
4'-O-β-maltotrioside (12) [16] in 46 and 35% yield. Compound 10 was glycosylated to daidzein 7-O-β-
maltoside (13) [16] and daidzein 7-O-β-maltotrioside (14) [16] in 39 and 30% yield by CGTase
(Figure 1).

Molecules 2010, 15
5156
2.2. Anti-allergic activity of β-glycosides of glycitein and daidzein
The effects of glycitein β-glycosides 2-7 on IgE antibody formation were investigated by an in vivo
bioassay using 7S-globulin from soybean as an antigen [17]. The average rat plasma IgE level after
treatment of 7S-globulin with or without test compounds was examined. As shown in Table 1,
glycitein 7-O-β-D-glucoside (3) and glycitein 7-O-β-maltoside (6) showed inhibitory action on IgE
antibody generation. On the other hand, glycitein 4'-O-β-D-glucoside (2), glycitein 4'-O-β-maltoside
(4), glycitein 4'-O-β-maltotrioside (5), and glycitein 7-O-β-maltotrioside (7) did not exhibit the
inhibitory action on IgE antibody formation. Next, the effects of daidzein β-glycosides 9-14 on IgE
antibody generation were investigated using the same bioassay systems described above. Only
daidzein 7-O-β-D-glucoside (10) showed inhibitory activity for IgE antibody formation. The 4'-O-β-D-
glucoside (9), 4'-O-β-maltoside (11), 4'-O-β-maltotrioside (12), 7-O-β-maltoside (13), and 7-O-β-
maltotrioside (14) of daidzein did not inhibit IgE antibody generation (Table 1).
Table 1. Suppressive action of β-glycosides of glycitein and daidzein 2-7 and 9-14 on IgE
antibody formation.
Compound
IgE levela
None
2
3
4
5
6
392.8 ± 120.7
382.2 ± 100.5
176.3 ± 87.0*
407.7 ± 126.2
453.0 ± 186.9
251.1 ±68.8
7
9
10
11
12
13
14
356.2 ± 188.8
397.5 ± 150.7
164.1 ± 78.5*
410.6 ± 188.0
435.7 ± 181.4
389.9 ± 145.5
400.8 ± 130.8
341.0 ± 122.5
Hydrocortisone
a
The results were expressed as average of plasma IgE level of 7 rats administered a total of
10 mg/kg of each test compound. Data are presented as mean ± SE. An asterisk indicates
significant differences from controls (*P < 0.05)
It has been reported that tocopheryl β-glycosides showed inhibitory effects on IgE antibody
formation [18,19]. Recently, we reported that 7-O-β-glycosides of genistein and quercetin showed anti-
allergic activities, whereas the β-glycosides whose sugar is attached at other phenolic hydroxyl groups,
exhibited no anti-allergic actions [20]. These findings suggested that the C-7 β-glucoside and
β-maltoside of glycitein and/or daidzein did not attenuate the anti-allergic activity, and that phenolic
hydroxyl groups at the 4'-position might be necessary for glycosides of glycitein and daidzein to act as
anti-allergic species. Studies on the anti-allergic mechanism(s) of the β-glycosides of glycitein and
daidzein synthesized here are now in progress.

Molecules 2010, 15
5157
2.3. Anti-oxidant activity of β-glycosides of glycitein and daidzein
The antioxidative activities of glycitein β-glycosides 2-7 and daidzein β-glycosides 9-14 were
determined by an in vitro bioassay of their DPPH radical scavenging activity. The antioxidant activities
were expressed as IC50 values and are summarized in Table 2. Glycitein 4'-O-β-D-glucoside (2),
glycitein 7-O-β-D-glucoside (3), daidzein 4'-O-β-D-glucoside (9), daidzein 7-O-β-D-glucoside (10)
showed DPPH free-radical scavenging activity, whereas the β-maltosides and β-maltotriosides of
glycitein and daidzein 4-7 and 11-14 had no antioxidant activity. The results obtained here suggested
that monoglucosides of glycitein and daidzein might be useful free-radical scavenging antioxidants
with high aqueous-solubility.
The superoxide-radical scavenging activity of glycitein β-glycosides 2-7 and daidzein β-glycosides
9-14 were expressed as IC50 values, summarized in Table 2. Glycitein 4'-O-β-D-glucoside (2),
glycitein 7-O-β-D-glucoside (3), and daidzein 4'-O-β-D-glucoside (9) showed superoxide-radical
scavenging activity. The results obtained here suggested that monoglucosides of glycitein and daidzein
could be potential superoxide-radical scavenging antioxidants.
Table 2. Antioxidant activities of glycitein β-glycosides 2-7 and daidzein β-glycosides 9-14.
IC50 (μM)
Compound
DPPH free-radical scavenging
Superoxide-radical scavenging
2
3
55
51
770
708
4
5
6
7
140
>200
>200
>200
76
>1,000
>1,000
>1,000
>1,000
829
9
10
45
767
11
12
13
14
155
>200
>200
>200
30
>1,000
>1,000
>1,000
>1,000
704
Vitamin C
3. Experimental
3.1. General
Glycitein and daidzein were purchased from Sigma-Aldrich Co. CGTase was purchased from
Amano Pharmaceutical Co. Ltd. The NMR spectra were recorded in DMSO-d6 using a Varian XL-400
spectrometer. The chemical shifts were expressed in δ (ppm) units referenced to tetramethylsilane. The
HRFABMS spectra were measured using a JEOL MStation JMS-700 spectrometer. HPLC was carried
out on a YMC-Pack R&D ODS column (150 × 30 mm) [solvent: CH3CN:H2O (3:17, v/v); detection:
UV (280 nm); flow rate: 1.0 mL/min].

Molecules 2010, 15
5158
3.2. Bacterial strain and culture conditions
Culture medium used for growth of L. delbrueckii subsp. bulgaricus (Okayama University of
Science) had the following composition (in grams per liter): 20 g of lactose, 5 g of yeast nitrogen base,
20 g of bacto casitone, 1 g of sorbitan monooleate, 2 g of ammonium citrate, 5 g of sodium acetate, 2 g
of K2HPO4, 0.05 g of MnSO4, 0.1 g of MgSO4. The cells were grown in the culture medium with
continuous shaking on a rotary shaker (120 rpm) at 30 °C.
3.3. Production of β-glucosides of glycitein and daidzein by L. delbrueckii
The cultures of L. delbrueckii were grown in 500 mL conical flasks containing 200 mL of culture
medium at 30 °C. Prior to use for the experiments, the cells were harvested by centrifugation at 8,000 g
for 15 min. The β-glucosides of glycitein and daidzein were prepared as follows: substrate
(0.2 mmol/flask, 2 mmol total) was added to ten 300 mL conical flasks containing L. delbrueckii cells
(5 g) and glucose (1 g) in freshly prepared culture medium (100 mL). The mixture was incubated with
continuous shaking on a rotary shaker (120 rpm) for 5 days at 30 °C. The reaction mixture was
centrifuged at 8,000 g for 15 min to remove the cells and the supernatant was extracted with n-butanol.
The n-butanol fraction was purified by preparative HPLC on YMC-Pack R&D ODS column to give
the β-glucoside products.
3.4. Production of β-maltooligosides of glycitein and daidzein by CGTase
To a solution containing β-glucosides of glycitein or daidzein (0.1 mmol) and starch (5 g) in sodium
phosphate buffer (25 mM, pH 7.0) was added CGTase (100 U). The reaction mixture was stirred at
40 °C for 24 h, and then the mixture was centrifuged at 3,000 g for 10 min. The supernatant was
subjected on to a Sephadex G-25 column equilibrated with water to remove CGTase. The fractions
containing glycosides were purified by preparative HPLC on YMC-Pack R&D ODS column to give
the β-maltooligoside products. Spectral data of new compounds are as follows:
Glycitein 4'-O-β-maltoside (4): FABMS m/z: 631.1640 [M+Na]+ (calcd 631.1639 for C28H32O15Na);
1H -NMR (DMSO-d6): δ 3.05-3.80 (12H, m, H-2'', 2''', 3'', 3''', 4'', 4''', 5'', 5''', 6'', 6'''), 3.92 (3H, s,
OCH3), 5.05 (1H, d, J = 3.2 Hz, H-1'''), 5.11 (1H, d, J = 7.6 Hz, H-1''), 7.00 (2H, d,
J = 8.0 Hz, H-3', 5'), 7.46 (1H, s, H-8), 7.51 (2H, d, J = 8.0 Hz, H-2', 6'), 7.75 (1H, s, H-5), 8.41 (1H, s,
13
H-2); C-NMR (DMSO-d6): δ 56.1 (OCH3), 60.7 (C-6'''), 60.8 (C-6''), 69.5 (C-4'''), 72.0 (C-2'''), 72.8
(C-5'''), 73.3 (C-2''), 73.5 (C-3'''), 75.3 (C-5''), 75.9 (C-3''), 80.5 (C-4''), 98.0 (C-1''), 100.5 (C-1'''),
101.1 (C-8), 105.0 (C-5), 115.1 (C-3', C-5'), 117.7 (C-10), 122.5 (C-1'), 124.6 (C-3), 130.3 (C-2', C-6'),
148.8 (C-6), 151.0 (C-9), 152.2 (C-7), 153.8 (C-2), 157.3 (C-4'), 178.1 (C-4).
Glycitein 4'-O-β-maltotrioside (5): FABMS m/z: 793.2170 [M+Na]+ (calcd 793.2167 for
1
C34H42O20Na); H-NMR (DMSO-d6): δ 3.09-3.85 (18H, m, H-2'', 2''', 2'''', 3'', 3''', 3'''', 4'', 4''', 4'''', 5'',
5''', 5'''', 6'', 6''', 6''''), 3.92 (3H, s, OCH3), 5.05 (1H, d, J = 3.2 Hz, H-1''''), 5.07 (1H, d, J = 3.0 Hz, H-
1'''), 5.12 (1H, d, J = 7.6 Hz, H-1''), 7.01 (2H, d, J = 8.4 Hz, H-3', 5'), 7.46 (1H, s, H-8), 7.50 (2H, d,
J = 8.4 Hz, H-2', 6'), 7.76 (1H, s, H-5), 8.41 (1H, s, H-2); 13C-NMR (DMSO-d6): δ 56.1 (OCH3), 60.5

Molecules 2010, 15
5159
(C-6''', C-6''''), 60.7 (C-6''), 69.5 (C-4''''), 71.5 (C-5'''), 72.0 (C-2'''), 72.4 (C-2'''', C-5''''), 73.0 (C-3''''),
73.3 (C-3'''), 73.8 (C-2''), 75.1 (C-5''), 75.9 (C-3''), 78.8 (C-4''), 78.9 (C-4'''), 98.1 (C-1''), 101.5 (C-1''',
C-1''''), 101.9 (C-8), 105.1 (C-5), 115.0 (C-3', C-5'), 117.6 (C-10), 122.5 (C-1'), 124.5 (C-3), 130.3
(C-2', C-6'), 148.7 (C-6), 151.0 (C-9), 152.2 (C-7), 153.8 (C-2), 157.6 (C-4'), 178.0 (C-4).
Glycitein 7-O-β-maltoside (6): FABMS m/z: 631.1641 [M+Na]+ (calcd 631.1639 for C28H32O15Na);
1H-NMR (DMSO-d6): δ 3.09-3.77 (12H, m, H-2'', 2''', 3'', 3''', 4'', 4''', 5'', 5''', 6'', 6'''), 3.90 (3H, s,
OCH3), 5.07 (1H, d, J = 3.2 Hz, H-1'''), 5.19 (1H, d, J = 7.6 Hz, H-1''), 7.01 (2H, d, J = 8.0 Hz, H-3',
5'), 7.46 (1H, s, H-8), 7.52 (2H, d, J = 8.0 Hz, H-2', 6'), 7.76 (1H, s, H-5), 8.41 (1H, s, H-2); 13C-NMR
(DMSO-d6): δ 56.1 (OCH3), 60.2 (C-6'''), 60.9 (C-6''), 69.7 (C-4'''), 72.0 (C-2'''), 72.7 (C-5'''), 73.3
(C-2''), 73.5 (C-3'''), 75.1 (C-5''), 75.9 (C-3''), 79.9 (C-4''), 98.8 (C-1''), 100.6 (C-1'''), 101.0 (C-8),
105.1 (C-5), 115.2 (C-3', C-5'), 117.7 (C-10), 122.5 (C-1'), 124.5 (C-3), 130.3 (C-2', C-6'), 148.8 (C-6),
151.0 (C-9), 152.5 (C-7), 153.8 (C-2), 157.0 (C-4'), 178.0 (C-4).
Glycitein 7-O-β-maltotrioside (7): FABMS m/z: 793.2177 [M+Na]+ (calcd 793.2167 for
1
C34H42O20Na); H-NMR (DMSO-d6): δ 3.05-3.88 (18H, m, H-2'', 2''', 2'''', 3'', 3''', 3'''', 4'', 4''', 4'''', 5'',
5''', 5'''', 6'', 6''', 6''''), 3.92 (3H, s, OCH3), 5.07 (1H, d, J = 3.2 Hz, H-1''''), 5.09 (1H, d, J = 3.2 Hz, H-
1'''), 5.19 (1H, d, J = 7.6 Hz, H-1''), 7.00 (2H, d, J = 8.4 Hz, H-3', 5'), 7.45 (1H, s, H-8), 7.51 (2H, d,
J = 8.4 Hz, H-2', 6'), 7.76 (1H, s, H-5), 8.41 (1H, s, H-2); 13C-NMR (DMSO-d6): δ 56.1 (OCH3), 60.5
(C-6''''), 60.7 (C-6'', C-6'''), 69.7 (C-4''''), 71.5 (C-5'''), 72.1 (C-2'''), 72.5 (C-2'''', C-5''''), 73.0 (C-3''''),
73.5 (C-3'''), 73.8 (C-2''), 75.1 (C-5''), 75.7 (C-3''), 79.7 (C-4''), 79.9 (C-4'''), 98.1 (C-1''), 100.5, 100.6
(C-1''', C-1''''), 101.9 (C-8), 105.1 (C-5), 115.0 (C-3', C-5'), 117.6 (C-10), 122.5 (C-1'), 124.5 (C-3),
130.2 (C-2', C-6'), 148.8 (C-6), 151.0 (C-9), 152.5 (C-7), 153.8 (C-2), 157.0 (C-4'), 178.1 (C-4).
3.5. Suppressive action on IgE antibody formation
The inhibitory action of β-glycosides of glycitein or daidzein on IgE antibody formation was
examined as follows: 7S-globulin was used as the antigen (1 mg/rat), and Al(OH)3 and pertussis
vaccine were used as the adjuvants (20 mg and 0.6 mL/rat, respectively). Sensitization was made by
injection of a mixture (0.6 mL) of the antigen and the adjuvant into the paws of each rat (male,
ca. 200 g). Paw edema was measured 24 h after injection and the treated rats were divided in groups
with an equal average swelling volume. Each sample was dissolved in physiological saline containing
10% Nikkol and the solution was injected daily into the rat for 11 d starting on the day of grouping.
Hydrocortisone was used as the positive control. The amount of IgE was measured by the passive
cutaneous anaphylaxis method on the 15th day [17]. The results were expressed as average of plasma
IgE level of 7 rats administered a total of 10 mg/kg of each test compound.
3.6. DPPH radical scavenging activity
DPPH free-radical scavenging activities of β-glycosides of glycitein or daidzein were determined as
follows: DPPH was dissolved in ethanol (500 μM) [21]. The sample solutions were prepared by
dissolving each compound in ethanol. To a solution containing various concentrations of each sample
(0.1 mL) and ethanol (0.9 mL) was added DPPH solution (1 mL) at room temperature. Vitamin C was

Molecules 2010, 15
5160
used as a positive control. After 20 min at 25 °C, the absorbance was measured at 517 nm. The
percentage reduction of the initial DPPH adsorption, i.e., the free-radical scavenging activity, was
calculated as follows: E = [(Ac − At)/Ac] × 100, where At and Ac are the respective absorbance at
517 nm of sample solutions with and without the test compounds. Antioxidant activity was expressed
as the 50% inhibitory concentration (IC50).
3.7. Superoxide-radical scavenging activity
Superoxide was generated by the xanthine-xanthine oxidase system [21]. Reaction mixture
contained 4 mM xanthine (50 μL), various concentration of sample in ethanol (50 μL),
2 mM nitro blue tetrazolium (NBT, 50 μL), of 0.3 nkat/mL xanthine oxidase (50 μL) and 0.1 M
phosphate buffer (pH 7.4) in a total volume of 2 mL. Vitamin C was used as a positive control. The
reaction mixture was incubated at 25 °C for 10 min and the absorbance was read at 560 nm. Percent
inhibition was calculated by comparing with control without test compound but containing the same
amount of alcohol. The IC50 value is shown as the sample concentration at which 50% of superoxide-
radical was scavenged.
4. Conclusions
The β-maltooligosaccharides of glycitein and daidzein were successfully produced through two-step
biocatalytic glycosylation by L. delbrueckii and CGTase. The 7-O-β-glucoside of glycitein and
daidzein and 7-O-β-maltoside of glycitein inhibited IgE antibody formation. On the other hand,
β-glucosides of glycitein and daidzein exerted DPPH free-radical scavenging activity and supeoxide-
radical scaventing activity.
References
1. Martin, M.P.; Horwitz, K.B.; Ryan, D.S.; McGuire, W.L. Phytoestrogen interaction with estrogen
receptors in human breast cancer cells. Endocrinology 1978, 103, 1860-1867.
2. Messina, M.J.; Persky, V.; Setchell, K.D.R.; Barnes, S. Soy intake and cancer risk: A review of
the in vitro and in vivo data. Nutr. Cancer 1994, 21, 113-131.
3. Adlercreutz, H.; Goldin, B.R.; Gorbach, S.L.; Höckerstedt, K.A.V.; Watanabe, S. Soybean
phytoestrogen intake and cancer risk. J. Nutr. 1995, 125, 757-770.
4. Molteni, A.; Brizio-Molteni, L.; Persky, V. In vitro hormonal effects of soybean isoflavones. J.
Nutr. 1995, 125, 751-756.
5. Adlercreutz, H.; Mazur, W. Phytoestrogens and Western diseases. Ann. Med. 1997, 29, 95-120.
6. Wang, C.; Kurzer, M.S. Phytoestrogen concentration determines effects on DNA synthesis in
human breast cancer cells. Nutr. Cancer 1997, 28, 236-247.
7. Barnes, S. Evolution of the health benefits of soy isoflavones. Proc. Soc. Exp. Biol. Med. 1998,
217, 386-392.
8. Kuiper, G.G.; Lemmen, J.G.; Carlsson, B.; Corton, J.C.; Safe, S.H.; van der Saag, P.T.; Burg, B.;
Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β.
Endocrinology 1998, 139, 4252-4263.

Molecules 2010, 15
5161
9. Setchell, K.D.R.; Cassidy, A. Dietary isoflavones: Biological effects and relevance to human
health. J. Nutr. 1999, 129, 758S-767S.
10. Marotta, F.; Mao, G.S.; Liu, T.; Chui, D.H.; Lorenzetti, A.; Xiao, Y.; Marandola, P. Anti-
inflammatory and neuroprotective effect of a phytoestrogen compound on rat microglia. Ann. N.
Y. Acad. Sci. 2006, 1089, 276-281.
11. Chacko, B.K.; Chandler, R.T.; D’Alessandro, T.L.; Mundhekar, A.; Khoo, N.K.; Botting, N.;
Barnes, S.; Patel, R.P. Anti-inflammatory effects of isoflavones are dependent on flow and human
endothelial cell PPARgamma. J. Nutr. 2007, 137, 351-356.
12. Kaminaga, Y.; Nagatsu, A.; Akiyama, T.; Sugimoto, N.; Yamazaki, T.; Maitani, T.; Mizukami, H.
Production of unnatural glycosides of curcumin with drastically enhanced water solubility by cell
suspension cultures of Catharanthus roseus. FEBS Lett. 2003, 555, 311-316.
13. Hollman, P.C.H.; Devries, J.H.M.; Vanleeeuwen, S.D.; Mengelers, M.J.B.; Katan, M.B.
Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J.
Clin. Nutr. 1995, 62, 1276-1282.
14. Morand, C.; Manach, C.; Crespy, V.; Remesy, C. Quercetin 3-O-beta-glucoside is better absorbed
than other quercetin forms and is not present in rat plasma. Free Radic. Res. 2000, 33, 667-676.
15. Hosny, M.; Rosazza, J.P.N. Novel isoflavone, cinnamic acid, and triterpenoid glycosides in
soybean molasses. J. Nat. Prod. 1999, 62, 853-858.
16. Li, D.; Park, J.H.; Park, J.T.; Park, C.S.; Park, K.H. Biotechnological production of highly soluble
daidzein glycosides using Thermotoga maritima maltosyltransferase. J. Agric. Food Chem. 2004,
52, 2561-2567.
17. Koda, A.; Miura, T.; Inagaki, N.; Sakamoto, O.; Arimura, A.; Nagai, H.; Mori, H. A method for
evaluating anti-allergic drugs by simultaneously induced passive cutaneous anaphylaxis and
mediator cutaneous reactions. Int. Arch. Allergy. Appl. Immunol. 1990, 92, 209-216.
18. Satoh, T.; Miyataka, H.; Yamamoto, K.; Hirano, T. Synthesis and physiological activity of novel
tocopheryl glycosides. Chem. Pharm. Bull. 2001, 49, 948-953.
19. Uhrig, R.K.; Picard, M.A.; Beyreuther, K.; Wiessler, M. Synthesis of antioxidative and anti-
inflammatory drugs glucoconjugates. Carbohydr. Res. 2000, 325, 72-80.
20. Shimoda, K.; Kobayashi, T.; Akagi, M.; Hamada, H.; Hamada, H. Synthesis of oligosaccharides
of genistein and quercetin as potential anti-inflammatory agents. Chem. Lett. 2008, 37, 876-877.
21. Ozsoy, N.; Candoken, E.; Akev, N. Implications for degenerative disorders: Antioxidative
activity, total phenols, flavonoids, ascorbic acid, β-carotene and β-tocopherol in Aloe vera. Oxid.
Med. Cell Longev. 2009, 2, 99-106.
Sample Availability: Contact the authors.
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).